

## COVID-19 Results Briefing

### India

April 15, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in India. The model was run on April 13, 2021, with data through April 12, 2021.

There was a declining trend in the number of daily COVID-19 cases and deaths in India from September 2020 to mid-February 2021, but after that there has been a reversal of this trend with a dramatic rise in April. Daily COVID-19 cases are now double the number in the previous peak in September 2020. The daily cases increased massively by 71% and daily deaths by 55% in India compared with last week. Without drastic measures to decrease social mixing and increase effective face mask use, the situation currently looks quite grim in India. IHME's reference scenario forecasts 665,000 COVID-19 deaths in India by August 1, 2021.

### Current situation

- Daily reported cases in the last week increased to 133,400 per day on average compared to 78,000 the week before (Figure 1).
- The estimated daily deaths in the last week increased to 1,500 per day on average compared to 970 the week before (Figure 2). This makes COVID-19 the number 5 cause of death in India this week (Table 1).
- The daily death rate is greater than 4 per million in Chhattisgarh, Maharashtra, and Punjab (Figure 3).
- We estimated that 24% of people in India have been infected as of April 12 (Figure 4).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in 29 states and union territories (Figure 5).
- The infection detection rate in India was close to 8% on April 12 (Figure 6).

### Trends in drivers of transmission

- Mobility last week was 24% lower than the pre-COVID-19 baseline (Figure 9). Mobility was near baseline (within 10%) in Sikkim and Uttarakhand. Mobility was lower than 30% of baseline in Chhattisgarh, Delhi, Gujarat, Madhya Pradesh, and Maharashtra (Figure 10).
- As of April 12, we estimated that 66% of people always wore a mask when leaving their home, based on an online Facebook survey (Figure 11). Mask use was lower than 50% in Arunachal Pradesh, Assam, Bihar, and Mizoram (Figure 12). These estimates may, however, not be generalizable to the entire population.
- There were 103 diagnostic tests per 100,000 people on April 12 (Figure 13).


- In India, 78% of people say they would accept or would probably accept a vaccine for COVID-19. This is up by 0.5 percentage points from last week. The fraction of the population who are open to receiving a COVID-19 vaccine ranges from 62% in Punjab to 85% in Uttarakhand (Figure 17).
- In our current reference scenario, we expect that 700 million will be vaccinated by August 1 (Figure 18).

## Projections

- In our **reference scenario**, which represents what we think is most likely to happen, our model projects 665,000 cumulative deaths on August 1, 2021. This represents 329,000 additional deaths from April 12 to August 1 (Figure 19). Daily deaths will peak at 5,600 on May 10, 2021 (Figure 20). These estimates are based in part on seroprevalence surveys.
- If **universal mask coverage (95%)** were attained in the next week, our model projects 70,000 fewer cumulative deaths compared to the reference scenario on August 1, 2021 (Figure 19).
- Under our **worse scenario**, our model projects 729,000 cumulative deaths on August 1, 2021, an additional 64,000 deaths compared to our reference scenario (Figure 19).
- By August 1, we project that 85,600 lives will be saved by the projected vaccine rollout.
- Figure 22 compares our reference scenario forecasts to other publicly archived models. Forecasts are widely divergent.


## Model updates

There are no major updates in the model this week.


**Figure 1.** Reported daily COVID-19 cases**Table 1.** Ranking of COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

Cause name	Weekly deaths	Ranking
Ischemic heart disease	29,214	1
Chronic obstructive pulmonary disease	17,278	2
Stroke	13,444	3
Diarrheal diseases	12,160	4
COVID-19	10,488	5
Neonatal disorders	8,423	6
Lower respiratory infections	8,340	7
Tuberculosis	8,128	8
Diabetes mellitus	5,252	9
Cirrhosis and other chronic liver diseases	5,193	10


**Figure 2.** Reported daily COVID-19 deaths and smoothed trend estimate.




**Figure 3.** Daily COVID-19 death rate per 1 million on April 12, 2021




**Figure 4.** Estimated percent of the population infected with COVID-19 on April 12, 2021



**Figure 5.** Mean effective R on April 01, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11-13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.



**Figure 6.** Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model.




\*Due to measurement errors in cases and testing rates, the infection to detection rate (IDR) can exceed 100% at particular points in time.




**Figure 7.** Percent of circulating SARS-CoV-2 for 3 primary variants on April 12, 2021.


**A. Percent B.1.1.7 variant**




**B. Percent B.1.351 variant**



**C. Percent P1 variant**



**Figure 8.** Infection fatality ratio on April 12, 2021. This is estimated as the ratio of COVID-19 deaths to infections based on the SEIR disease transmission model.



## Critical drivers

Table 2. Current mandate implementation

	All nonessential businesses closed	Any businesses restricted	Any gatherings restricted	Mask use	School closure	Stay home order	Travel limits
Andhra Pradesh							
Arunachal Pradesh							
Assam							
Bihar							
Chhattisgarh							
Dadra and Nagar Haveli and Daman and Diu							
Delhi							
Goa							
Gujarat							
Haryana							
Himachal Pradesh							
Jammu & Kashmir and Ladakh							
Jharkhand							
Karnataka							
Kerala							
Madhya Pradesh							
Maharashtra							
Manipur							
Meghalaya							
Mizoram							
Nagaland							
Odisha							
Punjab							
Rajasthan							
Sikkim							
Tamil Nadu							
Telangana							
Tripura							
Uttar Pradesh							
Uttarakhand							
West Bengal							

Mandate in place


Mandate in place (imposed this week)

No mandate


No mandate (lifted this week)

\*Not all locations are measured at the subnational level.


**Figure 9.** Trend in mobility as measured through smartphone app use compared to January 2020 baseline




**Figure 10.** Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on April 12, 2021




**Figure 11.** Trend in the proportion of the population reporting always wearing a mask when leaving home




**Figure 12.** Proportion of the population reporting always wearing a mask when leaving home on April 12, 2021




**Figure 13.** Trend in COVID-19 diagnostic tests per 100,000 people



**Figure 14.** COVID-19 diagnostic tests per 100,000 people on April 09, 2021



**Figure 15.** Increase in the risk of death due to pneumonia on February 1 2020 compared to August 1 2020




**Table 3.** The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our website (<http://www.healthdata.org/node/8584>).


Vaccine	Efficacy at preventing disease: D614G & B.1.1.7	Efficacy at preventing infection: D614G & B.1.1.7	Efficacy at preventing disease: B.1.351 & P.1	Efficacy at preventing infection: B.1.351 & P.1
AstraZeneca	75%	52%	10%	6%
CoronaVac	50%	43%	38%	25%
Janssen	72%	72%	64%	42%
Moderna	94%	85%	72%	47%
Novavax	89%	77%	49%	32%
Pfizer/BioNTech	91%	86%	69%	45%
Sinopharm	73%	63%	56%	36%
Sputnik-V	92%	80%	70%	45%
Tianjin	66%	57%	50%	32%
CanSino				
Other vaccines	75%	65%	57%	37%
Other vaccines (mRNA)	95%	83%	72%	47%




**Figure 16.** Trend in the estimated proportion of the adult (18+) population that have been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).



**Figure 17.** This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or is open to receiving a COVID-19 vaccine based on Facebook survey responses (yes and yes, probably).



**Figure 18.** The number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.



## Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:


- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the UK.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.

The **worse scenario** modifies the reference scenario assumptions in three ways:


- First, it assumes that variants B.1.351 or P1 begin to spread within 3 weeks in adjacent locations that do not already have B.1.351 or P1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The **universal masks scenario** makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.


**Figure 19.** Cumulative COVID-19 deaths until August 01, 2021 for three scenarios




**Figure 20.** Daily COVID-19 deaths until August 01, 2021 for three scenarios,



**Figure 21.** Daily COVID-19 infections until August 01, 2021 for three scenarios.



**Figure 22.** Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology (Delphi; <https://www.covidanalytics.io/home>), Imperial College London (Imperial; <https://www.covidsim.org>), The Los Alamos National Laboratory (LANL; <https://covid-19.bsvgateway.org/>), and the SI-KJalpha model from the University of Southern California (SIKJalpha; <https://github.com/scc-usc/ReCOVER-COVID-19>). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.



## More information

### Data sources:

Mask use data sources include [Premise](#); [Facebook Global Symptom Survey](#) (This research is based on survey results from University of Maryland Social Data Science Center) and the [Facebook United States Symptom Survey](#) (in collaboration with Carnegie Mellon University); Kaiser Family Foundation; [YouGov COVID-19 Behaviour Tracker](#) survey.

Vaccine hesitancy data are from the COVID-19 Beliefs, Behaviors, and Norms Study, a survey conducted on Facebook by the Massachusetts Institute of Technology (<https://covidsurvey.mit.edu/>).

Vaccine hesitancy data are from the [Facebook Global Symptom Survey](#) (This research is based on survey results from University of Maryland Social Data Science Center), the [Facebook United States Symptom Survey](#) (in collaboration with Carnegie Mellon University), and from the Facebook [COVID-19 Beliefs, Behaviors, and Norms Study](#) conducted by the Massachusetts Institute of Technology.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model [FAQ page](#).

### A note of thanks:

We wish to warmly acknowledge the support of [these](#) and others who have made our COVID-19 estimation efforts possible.

### More information:

For all COVID-19 resources at IHME, visit <http://www.healthdata.org/covid>.

Questions? Requests? Feedback? Please contact us at <https://www.healthdata.org/covid/contact-us>.